BIOMAT Database Logo BIOMAT Database Logo

[Chronic obstructive lung diseases associated with systemic arterial hypertension]. 1985

V F Kubyshkin, and S S Soldatchenko, and V I Konovalov

A total of 203 patients with chronic obstructive pulmonary diseases (COPD) with normal blood pressure (BP) as well as with systemic arterial hypertension of different character (labile and stable pulmonogenic essential hypertension) were examined. It was established that if COPD is associated with labile pulmonogenic hypertension and essential hypertension, the underlying disease runs a more benign course. In patients with COPD associated with normal BP or with labile pulmonogenic hypertension, use can be made of broncholytic drugs of different adrenoreceptor action. In associated COPD and stable pulmonogenic hypertension or essential hypertension it is desirable to administer selective stimulants of beta-2-adrenoreceptors, e.g. salbutamol.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008173 Lung Diseases, Obstructive Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent. Obstructive Lung Diseases,Obstructive Pulmonary Diseases,Lung Disease, Obstructive,Obstructive Lung Disease,Obstructive Pulmonary Disease,Pulmonary Disease, Obstructive,Pulmonary Diseases, Obstructive
D009921 Metaproterenol A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM. Orciprenaline,Alotec,Alupent,Astmopent,Metaprel,Metaproterenol Polistirex,Metaproterenol Sulfate,Orciprenaline Sulfate,Polistirex, Metaproterenol
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004837 Epinephrine The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS. Adrenaline,4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol,Adrenaline Acid Tartrate,Adrenaline Bitartrate,Adrenaline Hydrochloride,Epifrin,Epinephrine Acetate,Epinephrine Bitartrate,Epinephrine Hydrochloride,Epinephrine Hydrogen Tartrate,Epitrate,Lyophrin,Medihaler-Epi,Acetate, Epinephrine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000318 Adrenergic beta-Agonists Drugs that selectively bind to and activate beta-adrenergic receptors. Adrenergic beta-Receptor Agonists,beta-Adrenergic Agonists,beta-Adrenergic Receptor Agonists,Adrenergic beta-Agonist,Adrenergic beta-Receptor Agonist,Betamimetics,Receptor Agonists, beta-Adrenergic,Receptors Agonists, Adrenergic beta,beta-Adrenergic Agonist,beta-Adrenergic Receptor Agonist,Adrenergic beta Agonist,Adrenergic beta Agonists,Adrenergic beta Receptor Agonist,Adrenergic beta Receptor Agonists,Agonist, Adrenergic beta-Receptor,Agonist, beta-Adrenergic,Agonist, beta-Adrenergic Receptor,Agonists, Adrenergic beta-Receptor,Agonists, beta-Adrenergic,Agonists, beta-Adrenergic Receptor,Receptor Agonist, beta-Adrenergic,Receptor Agonists, beta Adrenergic,beta Adrenergic Agonist,beta Adrenergic Agonists,beta Adrenergic Receptor Agonist,beta Adrenergic Receptor Agonists,beta-Agonist, Adrenergic,beta-Agonists, Adrenergic,beta-Receptor Agonist, Adrenergic,beta-Receptor Agonists, Adrenergic
D000420 Albuterol A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol. Salbutamol,2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol,Albuterol Sulfate,Proventil,Sultanol,Ventolin
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive

Related Publications

V F Kubyshkin, and S S Soldatchenko, and V I Konovalov
[Central and regional hemodynamics in chronic obstructive lung diseases associated with systemic arterial hypertension].
January 1982, Sovetskaia meditsina,
V F Kubyshkin, and S S Soldatchenko, and V I Konovalov
[Chronic obstructive lung diseases and arterial hypertension].
January 1980, Archivio per le scienze mediche,
V F Kubyshkin, and S S Soldatchenko, and V I Konovalov
[Respiration in patients with chronic lung diseases in association with systemic arterial hypertension].
January 1983, Vrachebnoe delo,
V F Kubyshkin, and S S Soldatchenko, and V I Konovalov
[Myocardial function, systemic and pulmonary hemodynamics in chronic obstructive bronchitis associated with arterial hypertension].
January 1986, Klinicheskaia meditsina,
V F Kubyshkin, and S S Soldatchenko, and V I Konovalov
[24-Hour arterial pressure profile in chronic obstructive lung diseases in combination with arterial hypertension treated with enalapril].
January 2002, Terapevticheskii arkhiv,
V F Kubyshkin, and S S Soldatchenko, and V I Konovalov
[Pulmonary hypertension in chronic obstructive lung diseases].
January 1986, Sovetskaia meditsina,
V F Kubyshkin, and S S Soldatchenko, and V I Konovalov
Pulmonary hypertension associated with chronic lung diseases.
January 2016, Swiss medical weekly,
V F Kubyshkin, and S S Soldatchenko, and V I Konovalov
[Blood prostaglandins in patients with obstructive lung diseases and arterial hypertension].
January 1981, Terapevticheskii arkhiv,
V F Kubyshkin, and S S Soldatchenko, and V I Konovalov
Pulmonary Arterial Hypertension Therapy in Pulmonary Hypertension Associated With Lung Diseases.
May 2024, JACC. Asia,
V F Kubyshkin, and S S Soldatchenko, and V I Konovalov
[Increased arterial blood pressure in patients with chronic obstructive lung diseases].
June 1983, Klinicheskaia meditsina,
Copied contents to your clipboard!